Analysis of Pleiotropic Effects of Nivolumab in Pretreated Advanced or Recurrent Non-small Cell Lung Cancer Cases

Background/Aim: Nivolumab is an immune checkpoint inhibitor for advanced non-small cell lung cancer (NSCLC). We investigated the safety and efficacy of nivolumab by analyzing the response factor, adverse effects (AE), and the post-treatment condition of pretreated advanced or recurrent NSCLC patient...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:In Vivo
Main Authors: AKANO, YUMIKO, KURIBAYASHI, KOZO, FUNAGUCHI, NORIHIKO, KODA, YUICHI, FUJIMOTO, ERIKO, MIKAMI, KOJI, TOSHIYUKI, MINAMI, TAKAHASHI, RYO, YOKOI, TAKASHI, KIJIMA, TAKASHI
Formato: Artigo
Idioma:Inglês
Publicado em: International Institute of Anticancer Research 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6506318/
https://ncbi.nlm.nih.gov/pubmed/30804134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.11503
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados